

EVOLUTION OF IL-23 INHIBITORS FOR CROHN'S DISEASE MANAGEMENT

MARCH 9th, 2022 | h. 2:00 pm CET

Scientific directors: Silvio Danese, Laurent Peyrin-Biroulet

The evolution of biological drugs has made major steps forwards for the treatment of IBD, another mechanism of action is the biologic that inhibit IL-23 and new agents are now coming, new data on new monoclonal antibodies in IL23 are becoming available for the treatment of CD.

The aim of the course is to highlight the recent evolution of IL23 blockers for CD patients.

FACULTY

Silvio Danese

Professor of Gastroenterology,
Head of Gastroenterology and Endoscopy
San Raffaele Hospital, Milan, Italy

Laurent Peyrin-Biroulet

Full Professor of Medicine IBD Unit
Department of Gastroenterology Nancy
University Hospital, France

Edouard Louis

Professor and Head of the Gastroenterology
department at Liège University Hospital CHU Liège, Belgium

Sebastian Zeissig

Professor Department of Medicine I
University Medical Center Dresden, Germany

William Sandborn

Distinguished Professor of Medicine
Chief, Division of Gastroenterology Director,
UCSD IBD Center UC San Diego Health System, California

Welcome and Intro of meeting objectives 5'

Silvio Danese, *Italy* - Laurent Peyrin-Biroulet, *France*

Unmet need in Crohn's disease in 2021 15'

Edouard Louis, *Belgium*

IL-23 pathway in Crohn's disease 15'

Sebastian Zeissig, *Germany*

Novel IL-23 blockers

for Crohn's disease management 15'

William Sandborn, *California*

Q&A session 10'



[CLICK HERE
TO REGISTER](#)

Sponsored by

janssen  Immunology

PHARMACEUTICAL COMPANIES OF *Johnson & Johnson*



ORGANIZING SECRETARIAT
Materia Prima srl
www.materia1a.it
segreteria@materia1a.it